Diabetic kidney disease progresses despite blood pressure and glucose control, and steroidal mineralocorticoid antagonists carry hyperkalemia and hormonal side effects that limit their use. Kerendia (finerenone) was designed around those constraints.
Finerenone is the first nonsteroidal selective mineralocorticoid receptor antagonist, targeting the inflammation and fibrosis that drive progression rather than acting mainly on blood pressure. The once-daily tablet reduces the risk of kidney function decline, kidney failure, cardiovascular death, and heart failure hospitalization in adults with chronic kidney disease associated with type 2 diabetes.
Kerendia has since expanded into heart failure with preserved ejection fraction and faces no generic competition. It occupies a distinct pillar of therapy alongside SGLT2 inhibitors, making combination positioning and payer coverage the key dynamics to follow.
